News & Media

Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.

Image
Image

Media Contact:

Robert Murphy

Director, External Communications,
Otsuka America Pharmaceutical, Inc

Phone:
Email:
robert.murphy@otsuka-us.com
Press Release

Akebia Therapeutics, Inc. and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) accepted for filing the New Drug Application (NDA) for vadadustat for the treatment of anemia due to chronic kidney disease (CKD) in both adult patients on dialysis and adult patients not on dialysis.

Press Release

Amidst COVID-19, Mental Health Leaders, Policymakers Explore Innovations and Policy Solutions to Strengthen Access to Care for People Living with Serious Mental Illness

WASHINGTON, DC – May 12, 2021 – Otsuka America Pharmaceutical, Inc. (Otsuka), a global leader in developing solutions to meet unmet mental health needs, today hosted its third-annual Advancing Mental Health Policy: BetterTogether Forum. This live, virtual event brought together more than 300 elected officials, thought leaders and stakeholders from across the mental health community to discuss the impact of COVID-19 on people living with mental illness and policies for strengthening equitable access to behavioral health care.

US News

The Sozosei Foundation, a charitable foundation funded by Otsuka America Pharmaceutical, Inc., awarded $100,000 to the American India Foundation (AIF) COVID-19 Response Fund. This grant is drawn from Sozosei’s Disaster Relief and Recovery Philanthropy Program in response to India’s state of emergency, as the country records the highest number of cases and virus-related deaths globally.

Press Release

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announce the decision to continue the recruitment of patients in the phase III clinical trial of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type (NCT03548584). The decision to continue the trial is based on the results of an independent interim analysis, supporting to progress the trial to the planned full enrollment of 330 patients.